 - Initiation of Phase 12a Trial of CLS-AX axitinib injectable suspension for Wet Age-Related Macular Degeneration Expected by Year-End 2020 - - Phase 2 Trials Using SCS Microinjector Ongoing by Gene Therapy and Oncology Partners - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - 